INTRODUCTION
Pulmonary fibrosis is a potentially fatal disease characterized by continuous alveolar epithelial injury and dysregulated repair, leading to myofibroblast accumulation and excessive deposition of extracellular matrix and connective tissue. Previous studies have indicated that efficient alveolar epithelial cell repair is critical for normal healing without fibrosis. 1, 2 Because apoptotic cell recognition and clearance result in growth factor release and activation of signaling molecules involved in maintaining the epithelium and endothelium, the maintenance of alveolar integrity has been proposed to be critically dependent on intact mechanisms of apoptotic cell clearance. 3 Apoptotic cell recognition and efferocytosis by macrophages greatly influences the resolution of inflammation by affecting secretion of the anti-inflammatory cytokines, transforming growth factor-b (TGF-b) and interleukin (IL)-10, that inhibit inflammatory mediator production. 4, 5 In addition, the ability of macrophages to clear apoptotic cells involved in resolving inflammation is dependent on their programming to the alternative M2 phenotype. These macrophages exhibit increased expression and activity of macrophage-specific peroxisome proliferator-activated receptor-g (PPARg) that is essential to their alternative activation. [6] [7] [8] One mechanism by which apoptotic cells enhance efferocytic programming is through phosphatidylserine-dependent induction of IL-4 signaling that upregulates PPARg activation through production of 12/15-lipoxygenase-dependent 15-hyrdoxyoctadecadienoic acid (15-HETE). 9 PPARg is a member of the nuclear hormone receptor family that modulates gene expression upon ligand binding. Activation of PPARg has been linked to glucose homeostasis, 10 cellular differentiation, 11 apoptosis, 12 and antiinflammatory responses. 13 Within the lung, PPARg is expressed by the epithelium, smooth muscle cells, fibroblasts, endothelium, macrophages, eosinophils, and dendritic cells.
14 Several studies have demonstrated that PPARs play important roles in regulating processes related to fibrogenesis, including cellular differentiation, inflammation, and wound healing in vitro and in vivo. 15, 16 In particular, PPARg synthetic ligands interfered with Smad-dependent and -independent TGF-b signaling, thereby opposing the profibrotic effect of TGF-b. 17, 18 Administration of PPARg agonists markedly reduced expression of nitrotyrosine, poly(ADP ribose) polymerase activation, inducible nitric oxide synthase formation, and lung damage induced by bleomycin in mice. 19 On the other hand, PPARg agonists induced expression of the antifibrotic mediator, hepatocyte growth factor (HGF), via a peroxisome proliferator response element within the HGF promoter. 20 Moreover, these agonists upregulate the Smad corepressor TG-interacting factor (TGIF), leading to inhibition of a-smooth muscle actin (a-SMA) and fibronectin expression. 6 However, it remains unclear how this multipotent molecule PPARg prevents excessive fibrosis, thus leading to successful tissue repair, in the context of enhanced apoptotic cell recognition and clearance from the lesion.
Recently, the rodent bleomycin model of lung fibrosis allows the use of molecular tools to dissect the cellular and subcellular processes leading to fibrosis. 21 Interestingly, a single bleomycin instillation effectively replicates several of the specific pathogenic molecular changes associated with idiopathic pulmonary fibrosis, and may be best used as a model for patient with active disease. 22, 23 Nonetheless, in truth, the bleomycin model has never been promoted as an experimental equivalent of human idiopathic pulmonary fibrosis, a progressive interstitial lung disorder.
Here, we hypothesized that increased PPARg activation by apoptotic cell recognition and clearance programming reinforces the efferocytic ability of phagocytes, such as alveolar macrophages, thus hastening the resolution of pulmonary inflammation and fibrosis. To explore this hypothesis, we first characterized PPARg expression and activation in lung and alveolar macrophages following apoptotic cell instillation over the course of bleomycin-induced lung injury. Next, using a pharmacological approach involving a PPARg antagonist GW9662, we investigated the role of enhanced PPARg activation following apoptotic cell instillation in altering inflammatory and fibrogenic programs in alveolar macrophages and the lung, including the effects of PPARg on TGF-b, IL-10, and HGF, that are induced by apoptotic cells in vivo and in vitro.
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RESULTS
Immediate and sustained enhancement of PPARc expression following apoptotic cell instillation into bleomycin-stimulated lungs
Although PPARg mRNA and protein expression appeared to increase slightly in alveolar macrophages and lung tissue at 2 days after bleomycin treatment, these increases were not significant compared with the saline control (Figure 1a-c) . Apoptotic cell instillation further increased PPARg mRNA and protein expression relative to the bleomycin þ saline group. In contrast, viable cell instillation had no effect. In addition, confocal microscopy revealed an enhancement of nuclear PPARg staining in alveolar macrophages in bleomycin þ apoptotic cells compared with bleomycin þ saline or viable cells (Figure 1d ). In comparison, exposure to apoptotic cells did not affect the low levels of PPARg mRNA and protein present in lungs from naive mice (Figure 1a-c) .
To demonstrate that apoptotic cell induction is not restricted to T cells, we introduced apoptotic HeLa epithelial cells into bleomycin-stimulated lungs and then assessed PPARg mRNA and protein expression levels. Apoptotic HeLa epithelial cells exerted similar effects on PPARg mRNA and protein expression in lung tissue (Supplementary Figure S1a,b online) . Likely, no significant differences were observed with human Jurkat T cells and mouse thymocytes (Supplementary Figure S1c,d ). These findings suggest that apoptotic cellinduced PPARg expression is not dependent on cell type and the heterologous nature of the target apoptotic cells.
The kinetics of apoptotic cell-induced PPARg expression were also examined at days 7-21 after bleomycin treatment. PPARg mRNA in alveolar macrophages and lung tissue gradually increased up to 21 days after bleomycin treatment ( Figure 1e and Supplementary Figure S2a) . However, the apoptotic cell instillation further enhanced PPARg mRNA expression in alveolar macrophages and lung tissue each day after bleomycin treatment. Similarly, PPARg protein levels in lung tissue were further enhanced by apoptotic cells, reaching peak levels at day 21 ( Figure 1f) . As PPARg mRNA and protein levels followed similar kinetics after bleomycin treatment and apoptotic cell instillation, PPARg protein expression is likely regulated at the level of transcription.
As expected, lung PPARg mRNA and protein expressions were not statistically different between the bleomycin þ viable cells and bleomycin þ saline groups at days 7 and 14 after bleomycin treatment (Supplementary Figure S2b,c) . In addition, as all 10 mice treated with viable cells died within 21 days after bleomycin treatment, the effects between the two groups could not be compared.
Activation of PPARc and its target molecules are enhanced following apoptotic cell instillation into bleomycin-stimulated lungs Next, we examined whether nuclear PPARg activity was also enhanced by apoptotic cell instillation of lung tissue. PPARg activity was further enhanced in a similar temporal pattern by apoptotic cell instillation following bleomycin-induced lung injury (Figure 2a,b) . As expected, lung PPARg activity was not statistically different between the bleomycin þ viable cells and bleomycin þ saline groups on days 2, 7, and 14 after bleomycin treatment (Supplementary Figure S2d) .
As an indication of PPARg functional activity, we examined the expression of CD36, macrophage mannose receptor (MMR), and arginase 1 (Arg1), all of which are upregulated by PPARg and characteristic of alternative macrophage programming. 6, 27, 28 Our data demonstrate that these PPARg targets increased at the levels of mRNA and protein in alveolar macrophages and lung tissue at 2 h following apoptotic cell instillation ( Figure 2c Figure S3d,e) . Notably, the expression of these markers paralleled the pattern of PPARg expression in the bleomycin þ saline or apoptotic cell groups. To confirm that these target molecules are dependent on apoptotic cell-enhanced PPARg activity, the PPARg antagonist GW9662 was coadministered with apoptotic cells into the bleomycin-stimulated lungs. The enhanced activity of PPARg, as well as expression of these target molecules in alveolar macrophages and lung tissue, induced by introduction of apoptotic cells after bleomycin treatment was reduced by GW9662 treatment each day after bleomycin treatment. The inhibitor administered with buffer had no effects.
Cellular source of PPARc in the lung
Immunohistochemistry was performed on lung tissue using an anti-PPARg monoclonal antibody or an immunoglobulin G (IgG) isotype control to determine which cells express PPARg in this organ. PPARg expression was mainly localized to alveolar macrophages and, to some extent, lung parenchymal cells on days 7 and 14 after bleomycin treatment with saline (Supplementary Figure S4b,c) . Strong PPARg expression was observed in these cells following introduction of bleomycin þ apoptotic cells at these time points (Supplementary Figure S4e,f) . In contrast, PPARg staining was very weak in lung sections of unstimulated saline control animals (Supplementary Figure S4a) . No staining was observed in lung sections stained with the isotype control (Supplementary Endogenous apoptotic cells are generated and removed during an inflammatory reaction. Apoptotic neutrophils are likely the dominant cells being removed endogenously and alveolar Figure 2 Apoptotic cell instillation induces enhancement of peroxisome proliferator-activated receptor-g (PPARg) activity and its target molecule expression. After intratracheal instillation of saline alone (Sal) or apoptotic Jurkat cells (ApoJ) at 2 days after bleomycin (BLM) treatment, lavage supernatant was collected at 2 h after ApoJ instillation and on days 7, 14, and 21 after BLM treatment. Where indicated, the first dose of GW9662 (1 mg kg À 1 , intraperitoneally (i.p.)) was administered simultaneously with ApoJ instillation into BLM-stimulated lungs (2 days) and every day thereafter. PPARg activity in nuclear extracts from lung tissue was analyzed at (a) 2 h after ApoJ instillation and on (b) days 7, 14, and 21 after BLM treatment as described in Methods. The mRNA level of PPARg target molecules, including CD36 and arginase1 (Arg1), was analyzed by real-time PCR at (c and d) 2 h after ApoJ instillation and on (f and g) days 7 (7D), 14 (14D), and 21 (21D) after BLM treatment. Western blot analysis of CD36 and Arg1 protein in lung tissue homogenates at (e) 2 h after ApoJ instillation and on (h) days 7, 14, and 21 after BLM treatment. The relative densitometric intensity was determined for each band and normalized to a-tubulin. AM, alveolar macrophage. Values represent the mean ± s.e.m. from five mice in each group. *Po0.05 compared with saline control,
macrophages may be globally activated after bleomycin treatment. 25 Similar to the findings of our previous studies, 24 the phagocytic indices in alveolar macrophages from bleomycin þ apoptotic cells were significantly higher over the course of lung injury compared with treatment with bleomycin þ saline. 24 In this study, we evaluated the role of PPARg activation in increasing the efferocytic ability of alveolar macrophages.
Coadministration of GW9662 with apoptotic cells significantly reversed the enhanced efferocytic ability of alveolar macrophages on days 2 (Figure 4a ,c) and throughout days 7-21 after bleomycin treatment (Figure 4b) . Treatment with the inhibitor and buffers had no effect.
Cyclooxygenase-2 (COX-2)-induced production of prostaglandin E2 (PGE 2 ), which is the endogenous activator of Rac1, results in increased efferocytic capacity in vitro. 29 Thus, we examined whether the COX-2/PGE 2 pathway is involved in the apoptotic cell-induced efferocytic ability of alveolar macrophages. Coadministration of the COX-2 selective inhibitor NS-398, or the selective PGE 2 receptor EP2 inhibitor AH6809, did not alter efferocytosis of alveolar macrophages at 2 h after apoptotic cell instillation and on days 7-21 after bleomycin treatment (Figure 4a,b) .
PPARc activation mediates the anti-inflammatory response induced by apoptotic cell instillation
Studies have established PPARg as an inhibitor of activator protein-1, specific protein 1, and nuclear factor-kB-driven proinflammatory cytokine transcription.
6,30 Thus, we examined whether inhibition of apoptotic cell-enhanced PPARg activity affects tumor necrosis factor-a and macrophage inflammatory protein-2 expression in the lung. We also examined the effects of this inhibition on the inflammatory response, and this we investigated by assessing neutrophil numbers, total protein levels in bronchoalveolar lavage (BAL) fluid, and myeloperoxidase (MPO) activity in lung tissue. Coadministration of GW9662 reversed the reduction of tumor necrosis factor-a and macrophage inflammatory protein-2 mRNA in alveolar macrophages and lung tissue at 2 h after apoptotic cell instillation and 3 days after bleomycin treatment ( Figure 5a 
PPARc activation regulates proresolving cytokines after apoptotic cell instillation
The proresolution cytokines, TGF-b, IL-10, and HGF, are induced by apoptotic cell recognition and clearance. We have demonstrated that the presence of apoptotic cells upregulates TGF-b production during the early phase (days 2 and 3 after bleomycin treatment), but downregulates this cytokine during the fibrotic phase after bleomycin treatment. 19 In this study, we used an antagonist of PPARg to determine its role in the expression of these proresolving cytokines over time following apoptotic cell instillation. Coadministration of GW9662 reversed the enhancement of TGF-b mRNA in alveolar macrophages and lung tissue and the protein expression levels in BAL fluid following apoptotic cell instillation during the early phase (Figure 6a-f) . Moreover, the reduced levels of TGF-b mRNA and protein following apoptotic cell instillation were partially restored by GW9662 during the late fibrotic phase (days 14 or 21) (Figure 6d-f ). These data suggest that PPARg signaling is involved in apoptotic cell-induced TGF-b production at the transcriptional level during the early inflammatory phase and transcriptional repression during the late fibrotic phase following bleomycin treatment.
In comparison, the levels of IL-10 mRNA in alveolar macrophages and lung tissue, as well as protein levels in BAL fluid, were significantly increased at 2 days after bleomycin treatment. IL-10 expression peaked at day 7 before gradually declining until day 21. The expression of IL-10 remained higher than the saline-treated control group (Figure 6g-l) . The apoptotic cell instillation increased IL-10 mRNA expression in alveolar macrophages and lung to levels higher than that of the bleomycin þ saline group up to day 14. However, the protein levels in BAL fluid were significantly different on days 2, 3, and 
7 after bleomycin treatment. Apoptotic cell-induced IL-10 mRNA and protein levels peaked 7 days after bleomycin treatment. In contrast, instillation of viable cells did not alter baseline IL-10 protein levels (Supplementary Figure S2e) . Coadministration of GW9662 reversed apoptotic cellenhanced IL-10 mRNA and protein production on days 2, 3, and 7 after bleomycin treatment, reverting close to the levels exhibited by mice treated with bleomycin only. No significant difference between bleomycin þ apoptotic cells with or without GW9662 was observed during the late fibrotic phase.
Previously, we demonstrated that apoptotic cell instillation resulted in persistent induction of HGF mRNA and protein expression during bleomycin-induced lung fibrosis. 24 Moreover, inhibition of HGF signaling reversed the anti-inflammatory and antifibrotic effects of apoptotic cell instillation. 24, 31 Data from other studies indicated that PPARg agonists induced PPARg binding to the peroxisome proliferator response element in the HGF promoter region. 32 Thus, we examined the association between PPARg activity and HGF induction following apoptotic cell instillation. When GW9662 was coadministered with apoptotic cell instillation, the immediate and prolonged enhancement of HGF mRNA and protein were Figure 7e) . However, coadministration of GW9662 with buffer had no effect throughout the time period examined.
Helper T cell type 2 (Th2) cytokines, such as IL-4 and IL-13, may play an important role in the pathogenesis of pulmonary fibrosis. 33 Helper T cell type 1 (Th1) cytokine interferon-g (IFN-g) is thought to be an inhibitory modulator. 34, 35 We therefore assessed whether apoptotic cell-enhanced PPARg activity affects Th1/Th2 cytokine levels in BAL fluid. IL-4 and IL-13 protein levels increased significantly at 7 days and declined until 21 days after bleomycin treatment (Figure 7f,g) , consistent with the previous investigation. 36 Apoptotic cell instillation reduced bleomycin-induced increases in IL-4 and IL-13 levels on day 7 after bleomycin treatment. However, these cytokine levels were not significantly different on days 14 and 21 compared with the bleomycin þ saline group. Coadministration of GW9662 reversed partially the reduction of IL-4 and IL-13 in BAL fluid on day 7. In comparison, IFN-g levels in BAL fluid decreased slightly at 7, 14, and 21 days after bleomycin treatment compared with the saline group (Figure 7h) . Apoptotic cell instillation significantly enhanced the IFN-g levels on day 7 after bleomycin treatment. GW9662 reversed the enhanced IFN-g levels by apoptotic cell instillation at this time point.
PPARc activation mediates the antiapoptotic and antifibrotic effects of apoptotic cell instillation
Several studies have demonstrated that PPARg agonists prevent fibrogenesis in vitro and in vivo. 15, 16 Because our data demonstrate that apoptotic cell-enhanced PPARg signaling mediates persistent HGF production and biphasic TGF-b regulation, we next examined the role of PPARg in promoting the anti-apoptotic and antifibrotic effects of apoptotic cell instillation by assessing apoptotic activity and several fibrosis markers in experimental lung samples. In our previous study, we assessed DNA damage and apoptosis levels in lungs at day 7 after bleomycin treatment using TUNEL (TdT-mediated dNTP nick end labeling) staining. Apoptotic cell instillation reduced the number of TUNEL-positive alveolar epithelial cells. 24 In this study, the decrease in apoptosis levels was confirmed by measure of activities of caspase-3 and -9 and western blot analysis for the cleaved form of caspase-3 (Figure 8a-c) . Coadministration of GW9662 reversed reduction of activities of caspase-3 and -9 and cleaved caspase-3 expression at 7 days after bleomycin treatment. Moreover, the reduction of matrix markers of fibroproliferation, such as type 1 collagen a2 and fibronectin, and a marker of myofibroblast differentiation, a-SMA, at days 14 and 21 after bleomycin treatment was also reversed by GW9662 (Figure 8d) . Hydroxyproline, a marker of collagen content in lung tissue, was also restored by this inhibitor (Figure 8e) . Inhibitor alone had no effect. Furthermore, trichrome staining revealed that the reduction in collagenstained interstitial areas with damaged alveolar structures by apoptotic cell instillation at day 21 after bleomycin treatment was reversed by long-term PPARg inhibition (Figure 8f ).
PPARc activation enhances survival rate following apoptotic cell instillation
Of the mice treated with bleomycin, 50% and 85% died within 14 and 21 days, respectively ( Figure 9) . However, instillation of apoptotic cells reduced the death rate (15% and 20% mortality, respectively). However, coadministration of GW9662 with apoptotic cell instillation reversed reduction of the death rate (32% and 63% mortality, respectively).
DISCUSSION
The feasibility of cellular therapy based on the immunomodulatory properties of apoptotic cells has already been evaluated in different experimental models of acute and chronic inflammation to restore or induce immune tolerance. Indeed, the administration of apoptotic cells has been shown to attenuate lipopolysaccharide-induced acute lung injury or sepsis. 25, 37, 38 Moreover, apoptotic cell injection has also been used to reduce both the acute and chronic phases of inflammatory arthritis, 39 and insulitis in mice type-1 diabetes. 40 These beneficial effects have been attributed to the release of anti-inflammatory cytokines, such as TGF-b and IL-10, by macrophages upon apoptotic cell recognition and clearance. However, TGF-b1 production in alternatively activated macrophages has been linked to the development of pulmonary fibrosis. [41] [42] [43] Several studies have demonstrated that PPARg plays important roles in regulating processes related to fibrogenesis in vitro and in vivo.
14,15 Thus, important questions are raised regarding whether PPARg activation is enhanced by in vivo exposure to apoptotic cells over the course of lung injury, thereby leading to altered alveolar macrophage programming and, ultimately, hastening the resolution of both lung inflammation and fibrosis. Inflammatory responses have been associated with the initial stage of idiopathic pulmonary fibrosis. 44 Therefore, an effective treatment strategy for pulmonary fibrosis should be administrated during the early state. 45, 46 Indeed, in our preliminary studies, early exposure of apoptotic cells 2 days after bleomycin treatment provided significant effects on inflammatory responses, including neutrophil recruitment and total protein contents, and HGF production in BAL fluid, when examined on days 7 and 14 after bleomycin treatment (Supplementary Figure S7a-c) . However, little or no changes in these parameters were shown when apoptotic cells were exposed at 6 or 13 days after bleomycin treatment. Thus, based on this observation, apoptotic cells were instilled 2 days after bleomycin treatment not adding them at the late phase of inflammation and fibrosis induction.
We first characterized changes in PPARg expression and activation following apoptotic cell instillation over the course of bleomycin-induced lung injury. Genovese et al. 19 have demonstrated enhanced PPARg staining in lung sections obtained from bleomycin-treated mice. Interestingly, Standiford et al. 47 found higher PPARg mRNA levels and transcriptional activity in alveolar macrophages isolated from patients with acute lung injury compared with healthy control subjects. The administration of apoptotic cells has been shown to attenuate lipopolysaccharide-induced acute lung injury in mice. 25 Thus, it might be an important question of whether administration of apoptotic cells to patients with acute lung injury enhances the induction and activity of PPARg, then consequently resulting in resolution of inflammation and prevention of lung injury. In this study, we show that PPARg mRNA and protein levels in alveolar macrophages and lung tissue were immediately enhanced following instillation of apoptotic cells relative to bleomycin with or without viable cells. Moreover, the levels of PPARg mRNA and protein following early exposure to apoptotic cells increased gradually for up to 21 days after bleomycin treatment. However, the presence of viable Jurkat cells had no effect. These data demonstrate the specificity of PPARg induction for apoptotic cell recognition systems.
The factors that lead to upregulation of PPARg in the setting of bleomycin-induced lung injury are beyond the scope of this project, but a variety of endogenous ligands for PPARg such as fatty acids, PGD 2 -derived 15-deoxy-12,14 PGJ 2 (15d-PGJ 2 ), and lysophosphatidic acid can activate PPARg in a variety of cell types. 19, 47 Indeed, levels of PPARg and PPARg ligands, such as PGD 2 and 15-hyrdoxyoctadecadienoic acid (15-HETE) were elevated in alveolar macrophages isolated from patients with acute lung injury. 47 Similarly, in this study, we found that 15d-PGJ 2 in BAL fluid increased up to 14 days and slightly declined at 21 days after bleomycin treatment (Supplementary Figure S8a,b) . Many cell types in the lung are capable of expressing PPARg. Based on our results, alveolar macrophages are a primary source of PPARg following in vivo exposure to apoptotic cells. Moreover, immunohistochemistry and double immunofluorescence staining studies indicate that apoptotic cell-induced PPARg expression was observed mainly in macrophages and, to some extent, fibroblasts on days 7 and 14 after bleomycin treatment.
Concomitant with PPARg expression, immediate and prolonged enhancement of PPARg activity following apoptotic cell instillation was demonstrated in bleomycin-stimulated lung tissue. In support of this, enhanced expression of direct PPARg targets, including CD36, MMR, and Arg1, in alveolar macrophages and lung tissue following apoptotic cell instillation was greater than that observed following bleomycin with or without viable cells. Interestingly, all of these genes are known to be upregulated by PPARg activation and are characteristic of alternative macrophage programming. 6, 27, 28 Indeed, inhibition of PPARg activity by treatment with its antagonist GW9662 reversed apoptotic cell-enhanced mRNA and protein expression of these targets. Notably, the enhancement of phagocytic indices in alveolar macrophages after 2 h of in vivo exposure to apoptotic cells and up to 21 days after bleomycin treatment was restored to the levels seen in the bleomycin-only-treated group. However, inhibition of other signaling pathway, including the COX-2/PGE 2 pathway, did not reverse the enhanced phagocytic ability of alveolar macrophages. These data suggest that enhanced PPARg activity plays a critical role in inducing efferocytosis by alveolar macrophages following in vivo exposure to apoptotic cells. Consistent with this, previous studies have shown that macrophage-specific deletion of PPARg in mice also resulted in decreased apoptotic cell uptake.
6 GW9662 could also reverse the observed augmentation of efferocytosis in human macrophages induced by glucocorticoids. Thus, persistently enhanced PPARg activity following early in vivo exposure to apoptotic cells might strengthen apoptotic cell recognition and clearance system and prevent a defect in the ability of macrophages to clear them during bleomycininduced lung injury. Notably, in human pulmonary fibrosis, Morimoto et al. 48 showed that, like other chronic lung diseases, there is defective efferocytic ability and an increase in the number of apoptotic cells. However, the rate of neutrophil apoptosis as well as secondary necrosis along with efferocytic ability in the progress of human pulmonary fibrosis has not been reported. Nevertheless, the therapeutic use of apoptotic cells needs to be carefully considered in cases in which the capacity for apoptotic cell clearance is reduced during lung injury, and in which administered cells may progress into secondary necrosis that could exacerbate inflammation or injury. 49 The mechanisms by which PPARg activation mediates enhanced efferocytosis require further investigation. However, this biological process likely involves ligand or signalingdependent transactivation of efferocytic surface receptors and markers of alternative macrophage activation, such as CD36, MMR, and Arg1. 6, 27, 28 These data support an important and emerging concept that macrophage recognition of apoptotic cells can reinforce signaling pathways that shift their programming toward enhanced efferocytic ability in a feedback loop. 50, 51 One mechanism by which apoptotic cells enhance efferocytic programming is through phosphatidylserinedependent induction of IL-4 signaling that upregulates PPARg. 9 Autocrine stimulation by TGF-b produced in response to apoptotic cell recognition may similarly enhance PPARg expression. 26 These proposed mechanisms need to be verified in our in vivo experimental setting. Nevertheless, these hypotheses may not explain the effects observed during the late fibrotic phase as TGF-b and PPARg are regulated reciprocally after apoptotic cell instillation. In addition, it is possible that PPARg ligands, such as 15d-PGJ 2 and 15-HETE, might act as other factors to enhance PPARg expression following apoptotic cell instillation. However, the significant enhancement of 15d-PGJ 2 following apoptotic cell instillation was not observed during late inflammatory and fibrotic phases after bleomycin treatment (Supplementary Figure 8b) .
GW9662 restored the levels of proinflammatory mediators, including tumor necrosis factor-a and macrophage inflammatory protein-2, in alveolar macrophages, lung, and BAL fluid. Moreover, GW9662 inhibited apoptotic cell-induced neutrophil recruitment and enhancement of total protein in BAL fluid and MPO activity in the lung during early inflammatory phase. These data suggest that induction of the inflammatory response may be prevented by enhanced PPARg expression and activity following apoptotic cell instillation. The effects of PPARg activation may be mediated by several mechanisms. The anti-inflammatory action of PPARg agonism is reportedly mediated via its transrepression of proinflammatory mediator transcription. 6, 31 In addition, significant indirect effect via enhanced apoptotic cell recognition that then leads to the production of suppressive mediators, such as TGF-b and IL-10, might be even more significant. 25, 26, 52 Our study supports this concept as coadministration of GW9662 reversed apoptotic cell-induced TGF-b and IL-10 expression during early inflammatory phase after bleomycin treatment. These data suggest that enhanced PPARg activity upregulates efferocytosis in a positive feedback loop, leading to increased TGF-b and IL-10 gene expression and production that may be critical for regulating the activity of these anti-inflammatory mediators. However, further investigation is required to understand why IL-10 was upregulated for longer periods than TGF-b following apoptotic cell instillation in early inflammatory phase (peak response at 7 days for IL-10 vs. 3 days for TGF-b after bleomycin treatment). These results highlight the complexity of the effect of apoptotic cells as well as the possible involvement of various cross-talking networks that act on transcription and/or translation to produce these cytokines.
The fibroblast is now recognized as the key effector cell in the normal wound-healing process as well as the development of fibrosis. 53 Improper repair may result in dysregulated proliferation and activation of fibroblasts with increased expression of collagen and other matrix proteins. Myofibroblasts are recruited from a variety of sources including local mesenchymal cells, bone marrow progenitors (called fibrocytes), and via a process called epithelial-mesenchymal transition. Recent studies employing in vitro and in vivo approaches have revealed an entirely novel role for PPARg in fibrogenesis. Remarkably, both natural (15d-PGJ 2 ) and synthetic PPARg agonists inhibited TGF-b-driven myofibroblast differentiation and type I collagen protein production. 54, 55 In particular, Milam et al. 18 demonstrated that treatment of lung fibroblasts obtained from idiopathic pulmonary fibrosis patients or normal human controls with PPARg agonists results in inhibition of proliferative responses and induces cell cycle arrest. The PPARg agonist inhibited fibrosis, as assessed by measurement of lung hydroxyproline and collagen and by trichrome staining in the bleomycin-induced murine model. Thus, in our study, we could hypothesize that enhanced PPARg expression and activation following apoptotic cell instillation contributes to the prevention of excessive fibrosis, leading to successful tissue repair because of enhanced apoptotic cell recognition and clearance from the lesion. Indeed, coadministration of GW9662 reversed reduction in apoptotic activity, hydroxyproline contents, type 1 collagen a2, fibronectin, and SMA expression in lung tissue. The antifibrotic effect of apoptotic cell instillation via enhanced PPARg activity was confirmed by lung histology using trichrome staining of lung sections. PPARg agonists have been shown to induce the expression of HGF via a peroxisome proliferator response element in the HGF promoter 20, 32 and repress TGF-b-mediated myofibroblast activation. 56 Similarly, our data demonstrate that inhibition of PPARg activity by GW9662 reversed the immediate and prolonged increase in HGF mRNA and protein following apoptotic cell instillation. These findings emphasize that persistent amplification of HGF production after exposure to apoptotic cells is strengthened through additional PPARg signaling. In comparison, long-term inhibition of PPARg signaling partially reversed the reduction of TGF-b mRNA and protein levels induced by apoptotic cell instillation during late fibrotic phase after bleomycin treatment. However, administration of GW9662 with buffer alone had no effect throughout the time period investigated. These findings indicate that enhanced PPARg activity mimics the apoptotic cell-mediated effects on HGF and TGF-b production after bleomycin treatment. The mechanisms by which PPARg activity modulates reduced TGF-b expression by apoptotic cell instillation during fibrosis remain poorly understood in the context of enhanced efferocytosis. Nevertheless, it may be because of synergy of the transrepressive effects on TGF-b 30 and upregulation of HGF by greater and prolonged enhanced PPARg activity. Indeed, studies have reported that HGF decreases TGF-b mRNA and protein to promote epithelial cell survival 57 and inhibit epithelial-mesenchymal transition.
58,59
Previously, we found that long-term inhibition of HGF signaling reversed the decrease in TGF-b production induced by apoptotic cell instillation 21 days after bleomycin treatment. 31 On the other hand, as few effects on IL-10 levels were observed following apoptotic cell instillation with or without GW9662 at days 14 and 21 after bleomycin treatment, it remains possible that persistent, apoptotic cell-enhanced PPARg activity might contribute little to no changes in IL-10 expression during late fibrotic phase, even though this proresolving cytokine has been demonstrated to attenuate bleomycin-induced pulmonary fibrosis.
60
Th1/Th2 imbalance is proposed to be one of the hypothesis related to developing pulmonary fibrosis. 33, 36 We found that coadministration of GW9662 reversed the apoptotic cellinduced reduction of IL-4 and IL-13 levels and the enhancement of IFN-g levels in BAL fluid on day 7. These results suggest that enhanced PPARg activity contributes, at least in part, to improving the Th1/Th2 balance. Thus, apoptotic cell-induced PPARg activity may suppress initiation of a fibrotic response by regulating Th1/Th2 balance. In addition, oxidative stress may play an important role in the development of bleomycininduced fibrosis. Ligand-activated PPARg promotes the expression of antioxidant genes, such as manganese superoxide dismutase, glutathione peroxidase, heme-oxygenase 1, endothelial nitric oxide synthase, and the mitochondrial uncoupling protein 2. 61 Therefore, further studies are needed to determine the effects of enhanced PPARg activity by apoptotic cells on these antioxidant genes during bleomycin-induced pulmonary inflammation and fibrosis.
Our data demonstrated that apoptotic cell instillation after bleomycin treatment resulted in immediate and prolonged enhancement of PPARg mRNA and protein expression, accompanied by increased PPARg activity above the high basal levels found in bleomycin-stimulated lungs. The functional consequence of enhanced PPARg expression and activity, in turn, regulates the macrophage program of alternative activation with increased efferocytic surface receptors, including the PPARg target molecules, CD36, MMR, and Arg1. These effects reinforce the enhanced efferocytic ability of alveolar macrophages while reducing lung proinflammatory cytokine expression, neutrophil recruitment, total protein levels, and MPO activity. The additional complex molecular events provided by enhanced PPARg activity mediate the biphasic regulation of TGF-b during early and late phases, as well as upregulate IL-10 during the early inflammatory phase and HGF during both early and late phases following apoptotic cell instillation. A mechanism diagram summarizing and integrating the effects of enhanced PPARg activity following apoptotic cell instillation in bleomycin-induced lung fibrosis is shown in Figure 10 . Our study supports the concept that administration of apoptotic cells may be a potential tool with great therapeutic efficacy due to induction of PPARg shifting alternatively programmed alveolar macrophages associated with enhanced efferocytic ability and coordinated regulation of TGF-b, IL-10, and HGF in favor of resolving inflammation and preventing excessive, fibrotic outcomes.
METHODS
Reagents. Bleomycin and paraformaldehyde were purchased from Sigma-Aldrich (St Louis, MO). GW9662, NS398, and AH6809 (Cayman Chemical, Ann Arbor, MI) were used as supplied. The antibodies used for western blotting were as follows: anti-PPARg, anti-CD36, anti-MMR, anti-Arg1 (Cayman Chemical), anti-HGF (Santa Cruz Biotechnology, Santa Cruz, CA), and anti-a-tubulin (Sigma-Aldrich). 24,62 At 2 days after bleomycin treatment, saline alone or 10 Â 10 6 apoptotic or viable Jurkat cells in 50 ml saline were administered intratracheally through pharyngeal aspiration. 25, 49 Mice were killed 2 h after apoptotic cell instillation, as well as on days 7, 14, and 21 following bleomycin treatment (n ¼ 10 per group). Animals given apoptotic or viable human HeLa epithelial cells or mouse thymocytes were killed 2 h after apoptotic cell instillation (n ¼ 10 per group).
For the immediate inhibition experiments, the selective PPARg antagonist GW9662 (1 mg kg À 1 , intraperitoneally) 63 was administered simultaneously with intratracheal instillation of 10 Â 10 6 apoptotic cells 2 days after bleomycin treatment (n ¼ 10 per group). Mice were euthanized at 2 h after apoptotic cell instillation. For the long-term inhibition experiments, after the first dose of GW9662, the Figure 10 A mechanism diagram summarizing and integrating the effects of enhanced peroxisome proliferator-activated receptor-g (PPARg) activity following apoptotic cell instillation in bleomycin-induced lung fibrosis. Arg1, arginase 1; Col1, type 1 collagen a2; ECM, extracellular matrix; Fn, fibronectin; HGF, hepatocyte growth factor; IL-10, interleukin-10; MIP-2, macrophage inflammatory protein-2; MMR, macrophage mannose receptor; a-SMA, a-smooth muscle actin; TGF-b, transforming growth factor-b; TNF-a, tumor necrosis factor-a; Th1/Th2, helper T cell type 1/2.
inhibitor was administrated once a day, and mice euthanized on days 7, 14, and 21 after bleomycin treatment.
In efferocytosis assay experiments, the COX-2 selective inhibitor NS398 (3 mg kg À 1 , intraosseously) or the selective PGE 2 receptor EP2 antagonist AH6809 (5 mg kg À 1 , intraperitoneally) were administered simultaneously with instillation of 10 Â 10 6 apoptotic Jurkat cells 2 days after bleomycin treatment (n ¼ 10 per group) and mice were killed 2 h later. In long-term inhibition experiments, after the first dose, the inhibitor was administered twice a day (NS-398) or once a day (AH6809), and mice were killed on days 7, 14, and 21 after bleomycin treatment.
BAL cells, lung tissue, and cell counts. BAL was performed and cell counts were determined using an electronic Coulter Counter fitted with a cell sizing analyzer (Coulter Model ZBI with a channelizer 256; Coulter Electronics, Bedfordshire, UK). BAL cells were isolated and cytospun to assess phagocytic indices. 24, 25 The phagocytic index was calculated using the following formula: (number of apoptotic bodies)/ (200 total macrophages) Â 100. After BAL, lungs were removed, immediately frozen in liquid nitrogen, and stored at À 70 1C.
Induction of apoptosis. Human T lymphocyte Jurkat cells and HeLa epithelial cells were obtained from the American Type Culture Collection (Rockville, MD). Murine thymocytes were isolated from thymi of 4-week-old C57BL/6 mice by homogenizing the tissue through a 40-mm strainer to separate individual cells. Apoptosis was induced by ultraviolet irradiation at 254 nm for 10 min. The cells were then incubated for 2.5 h before use. They were B70% apoptotic by evaluation of nuclear morphology by light microscopy. 64 Alveolar macrophage culture. Suspended alveolar macrophages from mice were over 95% viable as determined by Trypan blue exclusion. Alveolar macrophages were isolated by adhesion (60 min). Table S1 ) for PCR amplifications were designed using Primer Express software (Applied Biosystems, Foster City, CA). All data were normalized to glyceraldehyde 3-phosphate dehydrogenase 52 and are reported as fold change in expression over the control group.
Semiquantitative reverse transcription-PCR. Total RNA was isolated from cultured cells using Invitrogen reagent solution (iNtRon Biotechnology, Seoul, Korea). The concentrations and purities of the RNA samples were evaluated by spectrophotometry. Reverse transcription was conducted for 60 min at 42 1C with 2 mg of total RNA using M-MLV reverse transcriptase (Enzynomics, Seoul, Korea). The primer sequences are listed in Supplementary Table S2 . Amplification was carried out using a GeneAmp PCR System 2400 (PerkinElmer, Waltham, MA). Samples were visualized on 1-2% agarose gels stained with ethidium bromide. The relative amounts, as compared with b-actin, were determined by densitometry.
Western blot analysis. Lung tissue homogenate samples were separated on 10% sodium dodecyl sulfate-polyacrylamide gels. Separated proteins were electrophoretically transferred onto nitrocellulose paper. The membranes were probed with specific antibodies to PPARg, CD36, MMR, Arg1, HGF, type 1 collagen a2, fibronectin, a-SMA, or a-tubulin and visualized by chemiluminescence.
Measurement of PPARg activity. PPARg activity was determined in nuclear extracts (8 mg) from lung tissue prepared using a kit and TRANSAM assay (Activ Motif, Carlsbad, CA) according to the manufacturer's instructions.
Caspase-3 and caspase-9 activities. The bioactivity of caspase-3 and caspase-9 was measured with a Fluorometric Assay Kit (ABcam, Cambridge, UK). In brief, lung homogenate samples were incubated with caspase-3 substrate DEVD-AFC or caspase-9 substrate LEHD-AFC. The fluorescence of the cleaved substrates was determined at an excitation wave length of 400 nm and an emission wave length of 505 nm.
Measurement of total protein concentration. Protein concentrations of the BAL samples were used as indicators of blood-pulmonary epithelial cell barrier integrity. Total protein content in BAL fluid was measured according to the manufacture's protocols.
Enzyme-linked immunosorbent assay (ELISA). BAL fluid samples were assayed using tumor necrosis factor-a, macrophage inflammatory protein-2, IL-4, IL-13, IFN-g, TGF-b1, IL-10, and HGF ELISA kits as per the manufacturer's instructions (R&D Systems, Minneapolis, MN). The activity of MPO in lung homogenates was estimated by using a specific ELISA kit.
Immunocytochemistry. PPARg protein expression was evaluated in cytospin preparations from freshly isolated alveolar macrophages by immunocytochemistry. Cells were fixed with 4% paraformaldehyde, permeabilized with Triton X-100, and stained with mouse monoclonal anti-PPARg antibody (Santa Cruz) overnight at 4 1C. Subsequently, cells were washed with phosphate-buffered saline three times and incubated with fluorescent isothiocyanate-conjugated donkey antirabbit IgG (Jackson ImmunoReseach, West Grove, PA). The slides were mounted in Vectashield mounting medium with 4',6-diamidino-2-phenylindole (Vector Laboratories, Youngstown, OH). All slides were imaged using a confocal microscope (LSM5 PASCAL; Carl Zeiss, Jena, Germany) equipped with a filter set with excitation at 488 and 543 nm.
Immunohistochemistry. From formalin-fixed, paraffin-embedded tissues, 4 mm sections were obtained. Slides were deparaffinized twice in xylene and rehydrated through graded ethanol solutions to distilled water. Sections were incubated with primary antibody against PPARg or control rabbit IgG at room temperature for 30 min, incubated with polymeric horseradish peroxidase-linker antibody conjugates as secondary antibodies, and then visualized using 3,3 0 -diaminobenzidine. To evaluate expression of PPARg on macrophages and fibroblasts, immunofluorescent staining for the macrophage-specific marker Mac3 (BD Pharmingen, San Jose, CA), fibroblast-specific marker S100A4 (Thermo Fisher Scientific, Fremont, CA), and PPARg was performed. The sections were incubated with Texas Red-conjugated anti-mouse IgG and fluorescein isothiocyanate-conjugated goat anti-rat IgG (Vector Laboratories). The sections were washed with Tris-buffered saline between all steps. The sections were mounted in Vectashield mounting medium with 4',6-diamidino-2-phenylindole. All slides were imaged using a confocal microscope.
Measurement of hydroxyproline. Lung hydroxyproline content was measured using a hydroxyproline assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) as per the manufacturer's instructions.
Lung histology. Lung tissue was fixed with 10% buffered formalin and embedded in paraffin. Masson's trichrome was used to stain 4 mm sections to evaluate inflammation and collagen deposition.
Statistical analysis. Values are expressed as the mean ± s.e.m. Analysis of variance was applied for multiple comparisons and Tukey's post hoc test was applied where appropriate. Student's t-tests were used for comparisons of two sample means. A P-value of o0.05 was considered statistically significant. All data were analyzed using JMP software (SAS Institute, Cary, NC). 
